



**Clinical Trials**

Daily Clinical Trials Updates  
Detailed Drug Pipelines  
[www.BiopharmInSight.com](http://www.BiopharmInSight.com)

**Eye illustrations**

Eye care related, stock and custom artwork for print and web marketing  
[www.jrehdesign.com](http://www.jrehdesign.com)

**Farmacie & legal?**

Uitdagend internationaal werk in R&D, patent / octrooi  
[www.synthon.com](http://www.synthon.com)

**Orthovita in Nederland**

Pro-Motion Medical in Zwijndrecht  
Excl distributeur voor Orthovita  
[www.pro-motionmedical.nl](http://www.pro-motionmedical.nl)

Search BioPortfolio:

Search



BioPortfolio



Web

- [Home](#)
- [Careers](#)
- [Conferences](#)
- [Directory](#)
- [Drug Discovery](#)
- [Genes](#)
- [InDepth](#)
- [Marketing](#)
- [News](#)
- [Reports](#)
- [Videos](#)
- [Search](#)
- [Contact](#)

- Channels
- [Business News](#)
- [News by Region](#)
- [News by Source](#)
- [News by Topic](#)
- [Health News \(A-Z\)](#)
- [Executive Reports](#)
- [Career Center](#)
- [Marketing Services](#)
- [Event Center](#)
- [Directories](#)
- [Disease Search](#)
- [Antibody Search](#)
- [Drug Discovery](#)
- [Investor tools](#)
- [Membership](#)
- [Search](#)
- [General](#)




**Body Organ Biomedical Corporation announces the prototype of bio cornea and enters the animal studies**

14 July, 2008---Taipei---Body Organ Biomedical Corporation, (BOBC, associate company of Aeon Astron Corporation) has confirmed the process and developed the prototype bio cornea. It is a porous structure, semi transparent, strong strength and 3-D structure collagen matrix. This bio cornea has tested in vitro and the cornea cell grows and perforated very in the demanded and structured way.

BOBC is now entering to animal study. Dr. Julio Lin, the research director at BOBC said: "this ologen™ bio artificial cornea is a biodegradable and bio safety product". This cornea will be in the end resolved and replaced by the patient's cornea that may totally bring bright to the blind that is caused by cornea disease or damage."

"Our aim is to make ologen™ bio cornea to meet the following requirements. Initially after it is implanted, due to the semi transparent structure and material, the blind can probably gain 10/100 more or less vision. With time passing, the vision can be much increased when the patient own cornea grown and this bio artificial is resolved." The total degradation time is about 6-9 months. Therefore, the patient will be able to see from the very first days and then developing to have good vision after that.

Due to the super ideal structure, the cornea may grow from outside into the central. We hope to get this matrix provides scaffolding for keratocyte migration, cellular cross-talk, and refraction. There is good flow for the nutrition and fluid distribution and this bio cornea can get the cell attachment and grow. The animal study is to demonstrate if this goal can be reached.



Ads by Google

**Biomedical Engineering**

BLA's, GMPs, Regulatory compliance Train with the leader!  
[www.cfpie.com](http://www.cfpie.com)

**Clinical Research Course**

Want a Career in Clinical Research? CRA Education & Training Program  
[www.CRA-Training.com](http://www.CRA-Training.com)

**Lifestream Pharma**

Distribueert innovatieve en bewezen zelfzorg producten in de Benelux.  
[www.lifestreampharma.net](http://www.lifestreampharma.net)


**Dedicated to Skin**

proDERM: Expert in clinical studies in dermatology & ophthalmology  
[www.proderm.de](http://www.proderm.de)

**Pharmaceutical Industry**

Leading Source for pharmaceutical industry market reports  
[www.Pharmalicensing.com](http://www.Pharmalicensing.com)





[www.delcornosas.com](http://www.delcornosas.com)  
Ads by Google

Picture:TOP is the SEM picture of the bio artificial cornea. BOTTOM is the almost transparent bio cornea prototype.

"There are 10 M blinds that caused from cornea damage or disease. The social, patient himself/herself and the family suffer from economy, emotion and many others. To get vision for the blind, it's a wonderful project" said Dr. Julio Lin, the project manager. The existing cornea transplantation is provided by the donors and nowadays the donors cornea are getting less applicable due to the LASIC surgery is popular. The bio cornea has great demand.

We are now working animal study with rabbit and pig. Several tests will be completed in 6 months. The human trial application will be followed afterward. Our aim is to get the approval in few years.

"This will save the social cost for the country and their family. The cost of blind is not only the losing production and also increasing the burden for the family and the country. It also makes the patient psychologically depressed." Mr. Lai continues. "The products we provide are all related to prevent avoidable blindness. The ologen™ collagen matrix is to enhance the glaucoma surgery success and the ologen™ bio cornea is for cornea blinded to see."

"The cornea researches have been very intensively taking in USA, EU, China and many other researches. It is a very competitive development and everyone is devoting all one's effort to it. This competition propels us to speed up the development. I hope we will be able to get into the clinical trial in 2009/2010 and hope this can save vision or bring vision to those who are in demand." Dr. Castro Gabriel, the medical director of Body Organ Biomedical Corp. comments.

For further information, please contact

[praae@aeonastron.net](mailto:praae@aeonastron.net)

Body Organ Biomedical Corp/Aeon Astron Corporation

Tel: +886 2 27717098

Fax: +886 2 27218516

Add: 17F, No. 248, Nanjing East Rd. Sec. 3, Taipei 105, Taiwan

Web: [www.ologen.com](http://www.ologen.com) , [www.aeonastron.com](http://www.aeonastron.com)

[Home](#) | [Marketing Services](#) | [News](#) | [Reports](#) | [Company Profiles](#) | [InDepth](#) | [Drug Discovery](#) |  
[Careers](#) | [Conferences](#) | [Videos](#) | [Search](#) | [Contact](#)

**Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See [User Agreement](#)**

Send comments and feedback to: [Peter Barfoot](#) Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501  
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883  
VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.

**BioPortfolio**